ketamine
Naltrexone in the Treatment of Ketamine Use Disorders: A Case Report and Literature Review (Verma, et al, 2025)
"findings consistent w/ 2 prior reports - use of naltrexone in KUDs at the dosage of 50 mg/day successfully helped patients achieve abstinence... naltrexone reduces antidepressant effects of ketamine, indicating overlap between opioid system & ketamine's NMDA receptor activity. "
psilocybin research
Spotlight: Psilocybin during the postpartum period induces long-lasting adverse effects in both mothers and offspring (in mice)
"we show that both parous parents and their children may be uniquely vulnerable to psychedelic treatment during the postpartum period"
psychedelic research
Spotlight: The Role of Psychedelics in Contemporary Psychological and Interdisciplinary Inquiry (Soylemez, et al, 2025)
"These compounds have been shown to enable access to unconscious cognitive and emotional content, facilitate emotional release, and induce a temporary dissolution of ego boundaries—processes that may underpin significant and enduring therapeutic outcomes."
iv ketamine
Spotlight: Efficacy of Intravenous Racemic Ketamine on Global Severity and Individual Symptoms of Depression: An Exploratory Retrospective Analysis (Landrum, et al, 2025)
" Maintenance intravenous racemic ketamine therapy demonstrated significant, persistent, and broad efficacy for treatment-resistant depression ...Side effect burden was no greater in higher doses as compared with lower. "
psychedelic cognitive behavioral therapy
Spotlight: Key competencies for psychedelic treatment in real-world mental health care settings (Wolff, et al, 2025)
"To accommodate mainstream adoption of these treatments, the competencies framework we present respects the distinctive contextual and cultural sensitivities of psychedelic care while remaining anchored in established psychotherapeutic, medical, and scientific paradigms."
mdma
Spotlight: Charting a New Frontier: Integrating Cognitive Behavioral Therapy Approaches with 3,4-methylenedioxymethamphetamine (MDMA)
"Psychedelics are being integrated with established cognitive behavioral therapies (CBTs).MDMA is a focus of recent research of psychedelic-assisted cognitive behavioral therapy.Six papers explore interesting and important questions on how to leverage the potential of psychedelics to augment CBTs."
ketamine
Spotlight: Ketamine's Role in Neuroinflammation and Neuroprotection Across Neurological and Psychiatric Disorders: A Narrative Review (Silva, et al, 2025)
"Our findings indicate that ketamine reduces excitotoxicity and inflammation, which may contribute to neuroprotection in acute neurological injuries. These insights underscore ketamine's potential as an adjunctive neuroprotective agent, warranting further clinical investigation...
dmt
Spotlight: N,N-dimethyltryptamine (DMT) mitigates experimental stroke by stabilizing the blood-brain barrier and reducing neuroinflammation (László, et al, 2025)
"Our findings prove that DMT mitigates a poststroke effect by stabilizing the BBB and reducing neuroinflammation. Such interactions of DMT with the vascular and immune systems can be leveraged to complement current, insufficient, stroke therapy."
iv ketamine
Spotlight: First study to compare two ketamine therapies for patients with severe depression
IV ketamine found to offer faster response with greater improvements than FDA-approved intranasal esketamine (Spravato)
ketamine
Characteristics of Ongoing Clinical Trials of Psychogenic Substances for Psychiatric Disorders (Havlik, et al, 2025)
"The most frequently studied substances were psilocybin (n=64; 35.4%) and ketamine (n=61; 33.7%). Trials were notably concentrated within a small number of leading academic institutions."
ketamine
Spotlight: Comparative Effects of Repeated Ketamine Infusion Versus Intranasal Esketamine in Patients With Treatment-Resistant Depression: A Retrospective Chart Review (Meisner, et al, 2025)
"In this naturalistic sample of patients with similarly severe TRD treated in a ketamine subspecialty service over a 4–5-week induction period, treatment with IV racemic ketamine was associated with a more rapid response and greater overall efficacy than treatment with IN esketamine."
lsd
Spotlight: Chris Bache: LSD and the Mind of the Universe
"experiences and insights from 73 high-dose LSD sessions conducted between 1979 and 1999"
ketamine
Spotlight: Ketamine's Therapeutic Role in Substance Use Disorders: A Narrative Review (Thomas, et al, 2025)
"...ketamine has been tested in nine RBCTs targeting cocaine, alcohol, opioid use disorder, and nicotine, suggesting efficacy for addiction in combination with psychotherapies, and often when doses produce subjectively reported mystical or psychedelic experiences."
ketamine
Ketamine/esketamine in the treatment of depression with comorbid borderline personality disorder or traits: A systematic review of effectiveness (Scott, et al, 2025)
"patients with depression and comorbid borderline personality disorder/traits were equally likely to respond to ketamine/esketamine as those with depression but without borderline personality disorder/traits."
ketamine
Exploring the Therapeutic Potential of Ketamine and Psilocybin in Comparison to Current Treatment Regimens for Treatment-Resistant Depression, Mood Disorders, and Post-traumatic Stress Disorder in the Pediatric Population (Hughes, et al, 2025)
"Ketamine's use for pediatric TRD demonstrated rapid-onset relief for signs and symptoms of depression in children and adolescents, and psilocybin also decreased symptoms in patients with longstanding or refractory depression. Ketamine has been well tolerated and exhibited symptom improvements"
ketamine
Psychedelics and mental health: reimagining care through science, insight, and compassion (Mikellides, et al, 2025)
"These substances are not stand-alone medications; rather, they function as adjuncts to intensive psychotherapeutic processes. Training therapists and establishing ethical, evidence-based protocols is essential."
ketamine
Mindfulness, music, visual occlusion in ketamine therapy for depression: do they change outcomes? A qualitative and quantitative analysis of a randomized controlled trial (Kheirkhah, et al, 2025)
"...participants in the combined sensory intervention group reported deeper engagement, a stronger sense of connection to reality, increased focus on the experience..., moments of relief from sadness, and feelings of awe and spiritual insight compared to the control group. "
ketamine
Ketamine Reduces Suicidality-Associated Emergency Department Utilization in Patients With Treatment-Resistant Depression: A 6-Month Mirror-Image Study (Patarroyo-Rodriguez, et al, 2025)
La ketamina reduce la utilización del departamento de emergencias asociada a la suicidabilidad en pacientes con depresión resistente al tratamiento: un estudio de imagen especular de 6 meses
